AC Immune, a Swiss biotech company that focuses on treatments for Alzheimer’s disease, has begun clinical trials for a vaccine that aims to prevent Alzheimer’s. The vaccine, named ACI-35, causes the immune system to produce antibodies which then target the tau protein within the brain. Many scientists believe that the tau protein can cause Alzheimer’s. AC Immune’s CEO Andrea Pfeifer has said “I would say however that in the next three to five years there should be a medication for Alzheimer’s.” Over 100 investigational Alzheimer’s drugs have failed in tests and clinical trials over the past 15 years. Currently there are no effective treatments for the prevention or hindrance of Alzheimer’s. The ACI-35 vaccine will be the first Alzheimer’s prevention vaccine to undergo clinical trials.
Read more here
